logo
Twitter
Discord
Email
logo
Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc.

NASDAQ•GYRE
CEO: Dr. Han Ying Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2006-04-12
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Contact Information
12770 High Bluff Drive, Suite 150, San Diego, CA, 92130, United States
619-949-3681
www.gyretx.com
Market Cap
$713.49M
P/E (TTM)
105.2
37
Dividend Yield
--
52W High
$13.75
52W Low
$6.11
52W Range
23%
Rank53Top 76.1%
2.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$30.56M+19.91%
4-Quarter Trend

EPS

$0.27+362.33%
4-Quarter Trend

FCF

$3.99M+306.21%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Growth Driven By Products Nine months 2025 Revenues reached $79.4M, up 2%, driven by $6.1M combined sales from Contiva® and Etorel®.
Strong Cash Position Maintained Cash and equivalents totaled $40.4M as of September 30, 2025; operations provided $6.6M cash flow for nine months.
Warrant Liability Impact Reduced Change in fair value of warrant liability decreased 65% to $2.4M gain for nine months ended September 30, 2025.
Common Stockholder Earnings Drop Net income attributable to common stockholders fell 45% to $6.8M for the nine months ended September 30, 2025.

Risk Factors

Profitability Declined Significantly Net income dropped 35% to $11.2M for nine months 2025, despite 2% revenue increase.
Core Product Sales Weakness ETUARY® revenue declined $4.4M for nine months 2025 due to marketing focus shift and market uncertainty.
High Customer Concentration Risk Sinopharm accounted for 50.3% of accounts receivable as of September 30, 2025, posing credit risk concentration.

Outlook

Hydronidone Trial Initiation Planned Anticipated initiation of the adaptive Phase 2/3 clinical trial for Hydronidone in the fourth quarter of 2025.
Etorel® Procurement Selection Etorel® selected in National Centralized Drug Procurement process; assessing potential impact on future operating performance.
R&D Investment Continues Committed $37.6M toward future R&D, including $12.9M for the Hydronidone program through September 30, 2025.

Peer Comparison

Revenue (TTM)

Arvinas, Inc.ARVN
$312.30M
+93.9%
Akebia Therapeutics, Inc.AKBA
$225.07M
+32.5%
Day One Biopharmaceuticals, Inc.DAWN
$133.67M
+30.4%

Gross Margin (Latest Quarter)

Arvinas, Inc.ARVN
100.0%
+0.0pp
Gyre Therapeutics, Inc.GYRE
94.7%
-1.6pp
Day One Biopharmaceuticals, Inc.DAWN
88.7%
-9.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TERN$3.09B-33.3-30.0%0.3%
OLMA$1.98B-14.4-41.5%1.3%
TYRA$1.62B-16.2-35.8%2.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.1%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 16, 2026
|
EPS:$0.08
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 7, 2025|
    Revenue: $30.56M+19.9%
    |
    EPS: $0.27+362.3%
    Meet
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 11, 2025|
    Revenue: $26.77M+6.1%
    |
    EPS: $0.01-87.9%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 9, 2025|
    Revenue: $22.06M-18.8%
    |
    EPS: $0.03-66.9%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 17, 2025|
    Revenue: $105.76M-6.8%
    |
    EPS: $0.14+109.9%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 13, 2024|
    Revenue: $25.49M-20.5%
    |
    EPS: $0.06+12.5%
    N/A
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 13, 2024|
    Revenue: $25.23M-3.5%
    |
    EPS: $0.04-48.4%
    N/A
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 13, 2024|
    Revenue: $27.17M+11.2%
    |
    EPS: $0.09+17.8%
    N/A
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 27, 2024|
    Revenue: $113.45M+10.9%
    |
    EPS: $-1.41-4784.4%
    Miss